https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-15 / Oncology (Williston Park, N.Y.) 2010 Nov;24(12):1161, 1166
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-15 / Oncology (Williston Park, N.Y.) 2010 Nov;24(12):1161, 11662010-11-15 00:00:002019-02-15 09:17:24Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-15 / Oncology (Williston Park, N.Y.) 2010 Nov;24(12):1149-55
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-15 / Oncology (Williston Park, N.Y.) 2010 Nov;24(12):1149-552010-11-15 00:00:002019-02-15 09:17:25Hyperthermia as a treatment for bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Int J Hyperthermia 2011;27(1):53-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Int J Hyperthermia 2011;27(1):53-622010-11-11 00:00:002019-02-15 09:17:22Hyperthermia enhances the effect of β-lapachone to cause γH2AX formations and cell death in human osteosarcoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-972010-11-11 00:00:002019-02-15 08:50:09An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-602010-11-11 00:00:002019-02-15 08:49:22Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Radiother Oncol 2010 Dec;97(3):535-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Radiother Oncol 2010 Dec;97(3):535-402010-11-11 00:00:002010-11-11 00:00:00Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-08 / Proc. Natl. Acad. Sci. U.S.A. 2010 Nov;107(47):20477-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-08 / Proc. Natl. Acad. Sci. U.S.A. 2010 Nov;107(47):20477-822010-11-08 00:00:002019-02-15 09:17:26NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-08 / Strahlenther Onkol 2010 Nov;186(11):587-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-08 / Strahlenther Onkol 2010 Nov;186(11):587-992010-11-08 00:00:002019-02-15 08:39:20Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Clin. Dev. Immunol. 2010;2010:517493
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Clin. Dev. Immunol. 2010;2010:5174932010-11-04 00:00:002019-02-15 08:52:55Dendritic cell-based immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Head Neck 2011 Oct;33(10):1394-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Head Neck 2011 Oct;33(10):1394-92010-11-04 00:00:002019-02-15 09:21:37Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
